Home > Insider Trading > Clovis Oncology Inc.

Clovis Oncology Inc. (CLVS)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
11 - 20
Next >>

Is Clovis Oncology Inc (CLVS) A Good Stock To Buy?

Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and...

Keep Reading →

June 13th, 2019 - Hedge Funds News

Here's What Hedge Funds Think About About Clovis Oncology Inc (CLVS)

"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87.

Keep Reading →

May 3rd, 2019 - Hedge Funds News

Argentiere Capital's Returns, AUM and Holdings

Deepak Gulati's Argentiere Capital is a Zug, Switzerland-based hedge fund launched back in June 2013, with an additional office in Chicago.

Keep Reading →

December 16th, 2018 - Hedge Fund Analysis Hedge Funds News

Should You Avoid Clovis Oncology Inc (CLVS)?

The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.

Keep Reading →

December 9th, 2018 - Hedge Funds News

How Clovis Oncology Inc (CLVS) Stacks Up Against Its Market Cap Peers

The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 30.

Keep Reading →

November 6th, 2018 - Hedge Funds News

Clovis Oncology Inc (CLVS) is Trending After TESARO Inc (TSRO) Results

Niraparib, which goes by the brand name Zejula, is an once-daily oral PARP inhibitor.

Keep Reading →

March 28th, 2017 - News

AstraZeneca PLC (ADR) (AZN)'s Lynparza Trial Results Positive In Competitive Threat To Clovis Oncology Inc (CLVS) And TESARO Inc (TSRO)

Lynparza, an ovarian cancer treatment developed by AstraZeneca PLC (ADR) (NYSE:AZN) has demonstrated its ability to slow down disease progression.

Keep Reading →

March 16th, 2017 - News Stock Analysis

Here's What Just Happened With AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) And Clovis Oncology Inc (CLVS)

It’s been a big week for PARP inhibitors. AstraZeneca PLC (ADR) (NYSE:AZN) just put out data from a phase 3 investigation of its lead PARP asset Lynparza, and the data came out as impressive.

Keep Reading →

March 15th, 2017 - News Stock Analysis

Clovis Oncology Inc (CLVS)'s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO)

According to Debjit Chattopadhyay, a Janney analyst, trials from AstraZeneca and Tesaro are likely to change the role of PARP inhibitors from being second to front-line treatments.

Keep Reading →

January 31st, 2017 - News Stock Analysis

Does Clovis Oncology Inc (CLVS) Represent a Good Addition to Your Portfolio?

The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small...

Keep Reading →

November 30th, 2016 - Hedge Funds News